Dupuy J, Lespine A, Sutra J F, Alvinerie M
Laboratoire de Pharmacologie-Toxicologie, INRA, BP 3, Toulouse, France.
J Vet Pharmacol Ther. 2006 Apr;29(2):107-11. doi: 10.1111/j.1365-2885.2006.00721.x.
The interaction of moxidectin (a macrocyclic lactone, ML) with P-glycoprotein (P-gp), multidrug resistance associated proteins (MRPs) and breast cancer resistance protein (BCRP) was studied in primary cultures of rat hepatocytes by measuring the intracellular accumulation of [14C]-moxidectin over 72 h in the presence of specific inhibitors: for P-gp, verapamil (10 microM); for MRPs, MK571 (100 microM), indomethacin (10 microM) and probenecid (3.8 mM); and for BCRP, fumitremorgin C (5 microM). The P-gp and MRP inhibitors increased significantly (P < 0.01) by 48.7%, 49.8%, 49.9% and 57.2% the area under the time-intracellular concentration curve (AUC) of moxidectin in rat hepatocytes, while the BCRP inhibitor, fumitremorgin C, had no effect on the AUC compared with the control. In addition, the mRNAs of all the drug transporters studied were detected in rat hepatocytes from 0 to 72 h. Using this cellular model it has been shown that MRP inhibitors increase moxidectin intracellular concentrations to a similar extent as the P-gp inhibitor. The identification of all the transporters that interact with MLs remains a challenge, which currently concerns several important therapeutic fields.
通过在特定抑制剂存在的情况下,测量大鼠原代肝细胞中[14C]-莫西菌素在72小时内的细胞内蓄积情况,研究了莫西菌素(一种大环内酯类药物,ML)与P-糖蛋白(P-gp)、多药耐药相关蛋白(MRPs)和乳腺癌耐药蛋白(BCRP)的相互作用。对于P-gp,使用维拉帕米(10微摩尔);对于MRPs,使用MK571(100微摩尔)、吲哚美辛(10微摩尔)和丙磺舒(3.8毫摩尔);对于BCRP,使用烟曲霉毒素C(5微摩尔)。P-gp和MRP抑制剂使大鼠肝细胞中莫西菌素的时间-细胞内浓度曲线下面积(AUC)显著增加(P < 0.01),分别增加了48.7%、49.8%、49.9%和57.2%,而BCRP抑制剂烟曲霉毒素C与对照组相比,对AUC没有影响。此外,在0至72小时内,在大鼠肝细胞中检测到了所有研究的药物转运蛋白的mRNA。使用该细胞模型已表明,MRP抑制剂使莫西菌素细胞内浓度增加的程度与P-gp抑制剂相似。鉴定所有与大环内酯类药物相互作用的转运蛋白仍然是一项挑战,这目前涉及几个重要的治疗领域。